Original version: https://www.mci-registrations.com/be-bruga/mci-registrations/scdm/files/gcdmp/en/2013/Full%20GCDMP%20Oct%202013.pdf
Executive Summary
The Society for Clinical Data Management (SCDM) is a non-profit professional organization founded to advance the discipline of clinical data management (CDM). The SCDM is organized exclusively for educational and scientific purposes. The mission of the SCDM, promoting clinical data management excellence, includes promotion of standards of good practice within clinical data management. In alignment with this part of the mission, the SCDM Board of Trustees established a committee to determine standards for Good Clinical Data Management Practices (GCDMP) in 1998. The committee charter reads as follows:
The review and approval of new pharmaceuticals by federal regulatory agencies is contingent upon a trust that the clinical trials data presented are of sufficient integrity to ensure confidence in the results and conclusions presented by the sponsor company. Important to obtaining that trust is adherence to quality standards and practices. To this same goal, companies must assure that all staff involved in the clinical development program are trained and qualified to perform those tasks for which they are responsible.
The discipline of Clinical Data Management includes paper and electronic case report form (CRF) design, clinical trials database design and programming, data standards, system implementation, data acquisition, data integration, into the clinical trials database, data review, validation, coding and database finalization. Independent of how individual companies perform these tasks within their company each company is obligated to ensure that the individuals performing these tasks follow Good Clinical Practices. However, currently prior to SCDM and this committee, there were no published good clinical practice guidelines specific to the discipline of Clinical Data Management. As the organization representing Clinical Data Management professionals in North America, SCDM is in a position to develop, maintain and publish GCDMP guidelines that define and promote current industry procedures and best practices.
One of the objectives of the committee is to develop, publish, and recommend use of guidelines for Good Clinical Data Management Practices. In addition to this stated objective of the GCDMP committee, it has been our continuing goal to obtain as much input and participation as possible from the SCDM members and other users to further develop GCDMP guidelines.
Over three years have passed since the September 2003 edition of the GCDMP was completed. During that time, the GCDMP Committee focused on the stability and future of the GCDMP and established a lifetime maintenance plan (LMP) to document the processes that guide changes. In an effort to keep the GCDMP current in a changing industry, this plan defines a formal process and timeline for review by the committee; the SCDM Board of Trustees; the international community, which is currently represented by the International Network of Clinical Data Management Associations (INCDMA); and the users. Four working subcommittees are defined in the LMP to assist in the maintenance of the GCDMP and the LMP itself.
In addition to planning for, writing, and putting in place the LMP, the GCDMP committee finalized a new chapter (“Metrics for Clinical Trials”) and revised five chapters. These updated chapters will be released when the review process has been completed.
The GCDMP is provided as a special service to the SCDM membership. The primary recipients include professionals involved in the pharmaceutical, biotechnology, and medical device clinical data management. It will provide assistance to data managers in their implementation of high quality data management processes and in their quest to become Certified Clinical Data Managers (CCDM). It will also provide management with a guide for planning training and education for new clinical data management staff.
Acknowledgements
As the committee chairperson, I would like to acknowledge the expertise, dedication and hard work of the document authors. The following individuals have contributed to one or more versions of the GCDMP: Susan Bornstein, Letitia Bowen, Sally Cassells, Anthony J. Costello, Wendy Cuthbert, Bernadette Farrell, Kaye Fendt, Lisa Freeman, Volker Freiman, Imogene Grimes, Marysasser Hedrick Holloway, Susan Howard, Becky Kush, Angel Lazarov, Terrence Loding, Meredith Nahm, Armelde Pitre, Don Rosen, Barbara Tardiff, Lisa Taylor, and Beth Wilson. In addition, Sasha Zucker provided his knowledge and skills as technical editor, for which we are most grateful. While I spearheaded the effort to update the Lifetime Maintenance Plan, Susan Howard led the Review and Update subcommittee, which dedicated its efforts to reviewing existing chapters and incorporating feedback from users. I would also like to acknowledge the GCDMP Full Committee, which has provided insight and expertise during the review of the new and revised chapters. Kaye Fendt—who initially took the idea of this committee to the Board of Trustees and to interested members of SCDM and who served as Board and FDA Liaison in its early years—has continued to lend her expertise to this committee as an innovator, an author, an editor, a supporter, and a motivator. Susan Bornstein led the committee during its formation and coordinated the creation of the CDM Task List, which served as the basis for the organization of this document. Meredith Nahm chaired the committee through 2001, served as Board Liaison through 2004, and has continued to contribute to the review process. Anthony Costello, who is currently Chair of the Board of Trustees and served as Board Liaison through 2006, continues to bring driven energy and focus on exposure and training of the document to the committee.
Special acknowledgements are extended to the users who offered helpful comments and feedback, the SCDM Board of Trustees, and the INCDMA members who participated in the review process. Without their continued interest and support, the GCDMP would not exist or be current. Administrative help (which includes providing the technical expertise needed to post the document and the Lifetime Maintenance Plan) was provided by SCDM’s management organization, including Kim Breitbach and Monica Drake.
We are most grateful to all of you for your contributions and dedication. Carol Garvey, GCDMP Committee Chair
Linda Talley, Board of Trustees Liaison
Introduction
The purpose of this document is to provide guidance on accepted practices for the many areas of CDM that are not covered by existing regulations and guidance documents. The intent is to remain consistent with regulatory practices in related areas of clinical research and to apply the concepts contained in those regulations and associated guidance documents to CDM. It is also the intent of the GCDMP to provide practical suggestions and proven means of meeting the guidelines recommended in the GCDMP. The GCDMP is written to serve the needs of multiple audiences including: data managers, data processors, statisticians, site personnel, clinical professionals, compliance auditors, regulatory affairs personnel, and all clinical research professionals making decisions regarding or using clinical trial data.
The GCDMP addresses the CDM areas of responsibility in 20 chapters. Each chapter includes two sections titled Minimum Standards and Best Practices respectively. These sections summarize the main recommendations of the chapter in bulleted form. For an executive summary or an overview of a chapter, read the chapter’s abstract, Minimum Standards, and Best Practices. The Minimum Standards ensure that data are complete, reliable, and processed correctly, otherwise known as data integrity. The Best Practices offer higher efficiency, quality, and function and lower risk in addition to assuring data integrity. The body of each chapter provides the rationale, technical details, and, often, discussion of alternate or common practices. References are provided at the end of each chapter to guide the reader to additional resources. Each chapter also contains recommended standard operating procedures (SOPs). Whether the SOPs are departmental or institutional in nature, it is the data manager’s responsibility to ensure that all data management concerns are addressed.
In the absence of CDM regulatory standards, it is important for experienced, professional data managers to provide thought leadership on accepted data quality levels, on practical methods of achieving them, and on the implications of new technology on the CDM tasks. Data management tasks are often technical and specialized. As the industry utilizes new technologies, it is therefore crucial that data management professionals take an active and forward-thinking role in setting appropriate expectations and standards for data quality, methodology for quantifying data quality, and auditing practices to ensure data quality.
The presence of acceptable quality standards becomes even more important as the industry undertakes larger trials where manual processes are no longer effective. New technologies often require not only retooling the data management process but also reforming the data management process to take advantage of the efficiencies offered by new technologies.
...
"Sự cần thiết về Thực tiễn quản lý dữ liệu lâm sàng tốt không phải là mới. Vào đầu những năm 1970, Dịch vụ Y tế Công cộng thừa nhận nhu cầu này thông qua hợp đồng với một trường đại học nghiên cứu lớn để đào tạo các nhà quản lý dữ liệu nghiên cứu. Tuy nhiên nhu cầu cần thay đổi theo thời gian và nhu cầu thực hành quản lý dữ liệu lâm sàng tốt trở nên quan trọng hơn vì ngành công nghiệp dược phẩm và thiết bị y tế và các cơ quan quản lý dựa nhiều hơn vào việc đánh giá dữ liệu lâm sàng truyền qua điện tử cho Quyết định dựa trên dữ liệu quan trọng. "
Như vậy, Hiệp hội Quản lý Dữ liệu lâm sàng cung cấp Good cấp Good Clinical Data Management Practices to Practices to the SCDM membership
Tài liệu này không đồng ý hoặc xác nhận bởi các cơ quan quản lý, các công ty dược phẩm hoặc công nghệ sinh học, các tổ chức nghiên cứu hợp đồng hoặc cộng đồng học thuật, mà là phản ánh quan điểm hiện tại về thành viên SCDM. Ngoài ra, không có khuyến cáo nào chứa trong văn bản này thay cho các quy định hoặc các hướng dẫn về quy định, cần luôn được tư vấn để đảm bảo tuân thủ. Tài liệu không nên được coi là một danh sách đầy đủ các chủ đề.
...
Các nguyên tắc của quản lý dữ liệu lâm sàng bao gồm paper and electronic case report form (CRF) design, clinical trials database design and programming, data standards, system implementation, data acquisition, data integration, into the clinical trials database, data review, validation, coding and database finalization. Độc lập về cách các công ty cá nhân thực hiện các nhiệm vụ này trong công ty của họ mỗi công ty có nghĩa vụ phải đảm bảo rằng các cá nhân thực hiện các nhiệm vụ này theo GCP. Tuy nhiên, hiện nay trước SCDM và ủy ban này, không có hướng dẫn GCP nào được công bố cụ thể cho kỷ luật Quản lý Dữ liệu Lâm sàng. Là tổ chức đại diện cho các chuyên gia quản lý dữ liệu lâm sàng ở Bắc Mỹ, SCDM có thể phát triển, duy trì và công bố các hướng dẫn GCDMP xác định và thúc đẩy các quy trình công nghiệp hiện tại và các phương pháp hay nhất.
...